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The Impact of Psoriasis on Pregnancy Outcomes
Xinaida T. Lima1,2, Vanitha Janakiraman3, Michael D. Hughes2 and Alexandra B. Kimball1
Psoriasis is an inflammatory disease that affects women in their reproductive years. Other similar diseases have
been associated with adverse pregnancy outcomes. We sought to assess whether pregnant women with
psoriasis are at higher risk of developing complications, such as preterm birth (PTB) and low birth weight (LBW).
A retrospective cohort, performed at two large tertiary centers, evaluated the outcomes of 162 pregnancies in
122 women with psoriasis and 501 pregnancies in 290 women without psoriasis. Univariable and multivariable
analyses, adjusting for important demographic factors, comorbidities, or a propensity score, were performed to
evaluate the association of psoriasis and a poor outcome composite (POC), including PTB (o37 gestational
weeks) and LBW (o2,500 g). Repeated measures analysis was used to account for the multiple pregnancies per
woman. Cesarean delivery, preeclampsia/eclampsia, and spontaneous abortion were also evaluated. For women
with psoriasis, there was a 1.89-fold increase in odds of POC (95% CI 1.06–3.39) in the univariable analysis. This
effect remained statistically significant in the multivariable analyses. Psoriasis was not associated with cesarean
delivery, preeclampsia/eclampsia, and spontaneous abortion. This study has shown higher odds of POC in
patients with psoriasis. Further larger population-based studies are required to confirm these findings.
Journal of Investigative Dermatology (2012) 132, 85–91; doi:10.1038/jid.2011.271; published online 15 September 2011
INTRODUCTION
Psoriasis is a chronic relapsing skin disease that affects 2–3%
of the American population. About 50% of these patients are
women and the majority of them have onset of disease before
40 years of age, coinciding with the reproductive years
(Henseler and Christophers, 1985; Koo, 1996). In the United
States, there is an estimated total of 65,000 to 107,000 births
a year to women with psoriasis (Horn et al., 2009). These
women may be at increased risk during their pregnancies;
psoriasis has been associated with several comorbidities,
such as metabolic syndrome, diabetes, cardiovascular
disease, and other inflammatory diseases including inflam-
matory bowel disease and an inflammatory arthritis, psoriatic
arthritis. An analysis of a prospective cohort of pregnant
women also showed that psoriasis was associated with higher
rates of depression, obesity, and smoking, potentially con-
tributing to a higher chance of developing an adverse
pregnancy outcome (Bandoli et al., 2010).
In addition to these comorbidities, the inherent inflamma-
tion of psoriasis may be a problem. Psoriasis is characterized
by an immuno-mediated inflammatory process that can
affect not only the skin and joints but can also lead to a
systemic inflammatory milieu, especially in moderate to
severe disease. C-reactive protein, fibrinogen, and other
inflammatory cytokines and cells can be found systemically
in patients with psoriasis, and their levels seem to correlate
with cutaneous disease activity (Rocha-Pereira et al., 2004;
Strober et al., 2008; Kagami et al., 2010).
Inflammation can be associated with adverse outcomes of
pregnancy, such as preterm birth (PTB) and low birth weight
(LBW). Proinflammatory cytokines known to be elevated with
active psoriasis, such as IL-6, C-reactive protein, and tumor
necrosis factor-a, have been shown to be increased, either in
the mother’s serum or in the cord blood, in pregnancies that
result in PTB or small-for-gestational-age neonates (Sorokin
et al., 2010; Amarilyo et al., 2011; Bastek et al., 2011). In
addition, other inflammatory diseases that have similar
immuno-mediated mechanisms, such as inflammatory bowel
disease and rheumatoid arthritis, have been associated with
PTB and LBW (Cornish et al., 2007; Mahadevan et al., 2007;
Lin et al., 2010; Norgaard et al., 2010).
This study sought to assess whether psoriasis diagnosed
before pregnancy is associated with higher odds of poor
outcomes of pregnancy, including PTB and LBW, and the
impact of psoriasis severity on these outcomes.
RESULTS
Patient characteristics
A total of 412 women were included in the analysis. The
psoriasis and non-psoriasis groups had 162 pregnancies in
122 women and 501 pregnancies in 290 women, respec-
tively. More women in the psoriasis group had only one valid
pregnancy for the main analysis, most likely because
pregnancies occurring before the diagnosis of psoriasis
were excluded. For the non-psoriasis group, pregnancies
were excluded only if the delivery was not at Partners
Healthcare System (PHS) or occurred before January 1999.
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Characteristics of both groups are presented in Tables 1 and 2.
The psoriasis group had a significantly higher proportion of
women who were white, older than 35 years, obese, users of
narcotics/psychotropic medications during pregnancy, and a
lower proportion of women who had only completed primary
or high school and who had anemia.
Univariable analysis
Among 162 pregnancies in women with psoriasis, 23 (14.2%)
either had PTB or LBW. Among 501 pregnancies in the non-
psoriasis group, 40 (8.0%) had this poor outcome composite
(POC). Psoriasis was significantly associated with POC, with
crude odds ratio (OR; 95% confidence interval) of 1.89
(1.06–3.39). None of the remaining variables had statistically
significant association with the main outcome (Table 3).
In a sensitivity analysis, including only women’s first valid
pregnancies, 18 (14.8%) and 23 (7.9%) women in the psoriasis
and non-psoriasis groups, respectively, had the POC, with a risk
difference of 6.8%. In the univariable analysis, psoriasis remained
significantly associated with POC (OR 2.01, 1.04–3.88).
Multivariable analysis: primary outcome
In the first multivariable model for the POC, we evaluated the
effect of psoriasis while adjusting for a priori selected
variables: age, race, and assisted reproductive technologies,
based on prior knowledge and expert experience. Psoriasis
was independently associated with the POC, adjusted OR of
1.95 (1.10–3.46). The other variables were not statistically
associated with the outcome (Table 4). All the remaining
covariates were evaluated for confounding, but none
matched the criteria and therefore were not included in this
multivariable model. In a multivariable model for the POC in
the first valid pregnancies, the effect of psoriasis was similar
but not statistically significant, with an adjusted OR of 1.91
(0.98–3.72).
In the next multivariable model, we assessed the effect of
psoriasis in the POC while adjusting for a propensity score
containing all potential confounders for which information
had been collected. After checking that adjusting for the
propensity score made all covariates become balanced
between the two exposure groups (no significant differences),
we fitted a multivariable model with just psoriasis and the
propensity score as predictor variables. The effect of psoriasis
remained statistically significant, with an adjusted OR of 2.02
(1.09–3.76; Table 5).
Multivariable analysis: secondary outcomes
Other outcomes were evaluated using multivariable models
(Table 5). At first, we assessed the effect of psoriasis, adjusting






White, n (%) 98 (80.3) 200 (69.0)
Hispanic, n (%) 11 (9.0) 49 (16.9)
Black, n (%) 4 (3.3) 17 (5.9)
Asian, n (%) 8 (6.6) 19 (6.6)
Marital status (married), n (%) 104 (85.2) 234 (80.7)
Educational level
Primary, n (%) 1 (1.0) 6 (2.6)
High school, n (%) 10 (10.3) 35 (15.2)
College, n (%) 69 (71.1) 124 (53.9)
Graduate school, n (%) 17 (17.5) 65 (28.3)
Valid pregnancies per woman1
1, n (%) 85 (69.7) 123 (42.4)
2, n (%) 33 (27.0) 130 (44.8)
3, n (%) 4 (3.3) 30 (10.3)
4, n (%) 0 7 (2.4)
Depression, n (%) 13 (10.7) 35 (12.1)
Hypertension, n (%) 0 3 (1.0)
1Pregnancies that met eligibility criteria.






Age (older than 35 years),
n (%)




8 (4.9) 3 (0.6)
Normal (18.5 to 24.9),
n (%)
89 (54.9) 325 (64.9)
Overweight (25 to 29.9),
n (%)
24 (14.8) 100 (20.0)
Obese 1 (30 to 34.9), n (%) 21 (13.0) 43 (8.6)
Obese 2 (35 to 39.9), n (%) 8 (4.9) 16 (3.2)
Obese 3 (X40), n (%) 6 (3.7) 2 (0.4)
Hospital of delivery (MGH),
n (%)
76 (46.9) 285 (56.9)
Diabetes, n (%) 3 (1.9) 10 (2.0)
IUI or IVF, n (%) 10 (6.2) 24 (4.8)
Substance abuse/cigarette
smoking, n (%)
15 (9.3) 31 (6.2)
Medication use, n (%) 6 (3.7) 36 (7.2)
Anemia, n (%) 33 (20.4) 152 (30.3)
Infection, n (%) 7 (4.3) 26 (5.2)
Abbreviations: BMI, body mass index; IUI, intrauterine insemination;
IVF, in vitro fertilization; MGH, Massachusetts General Hospital.
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for the same propensity score, on each component of the
POC separately. Women with psoriasis had higher odds of
PTB and LBW; however, these associations were not
statistically significant, with respective adjusted OR of 1.67
(0.82–3.39) and 2.08 (0.94–4.57).
The number of pregnancies in which women developed
preeclampsia/eclampsia was small: 9 (5.7%) in the psoriasis
group and 26 (5.2%) in the non-psoriasis group, and the
numbers were too small to enable fitting of a multivariable
model.
There were 46 (28.4%) and 159 (31.7%) cesarean
deliveries among all pregnancies in the psoriasis and non-
psoriasis groups, respectively. The multivariable analysis,
using a new propensity score that included all covariates and
an indicator variable for when the cesarean section was
performed as an electively repeated procedure, showed no
significant association with psoriasis (OR of 0.79, 0.47–1.33).
In the analysis of spontaneous abortions, among 439
women’s first pregnancies at PHS, there were 13 (9.3%) and
21 (7.0%) spontaneous abortions in the psoriasis and non-
psoriasis groups, respectively. In the multivariable model,
Table 3. Univariable analysis
POC, n (%)
Unadjusted
OR 95% CI P-value
Psoriasis
Yes (n=162) 23 (14.2) 1.89 1.06–3.39 0.032
No (n=501) 40 (8.0)
Age
435 Years (n=215) 18 (8.4) 0.83 0.46–1.51 0.541
o 35 Years (n=448) 45 (10.0)
Race
Non-white (n=155) 16 (10.3) 1.06 0.55–2.06 0.857
White (n=499) 46 (9.2)
BMI
Overweight (n=124) 7 (5.6) 0.60 0.27–1.32 0.202
Obese (n=96) 14 (14.6) 1.56 0.75–3.26 0.234
Normal (n=414) 40 (9.7)
Depression
Yes (n=77) 8 (10.4) 1.04 0.43–2.51 0.939
No (n=583) 55 (9.4)
Substance abuse
Yes (n=46) 6 (13.0) 1.52 0.59–3.91 0.382
No (n=614) 57 (9.3)
Diabetes
Yes (n=13) 3 (23.1) 1.87 0.65–5.36 0.242
No (n=650) 60 (9.2)
Assisted reproduction
Yes (n=34) 2 (5.9) 0.65 0.16–2.66 0.550
No (n=620) 59 (9.5)
Infection
Yes (n=33) 0 — — —
No (n=611) 61 (10.0)
Anemia
Yes (n=185) 18 (9.7) 1.06 0.55–2.05 0.867
No (n=452) 40 (8.8)
Medications
Yes (n=42) 6 (14.3) 2.11 0.85–5.23 0.106
No (n=428) 36 (8.4)
Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio;
POC, poor outcome composite.





OR 95% CI P-value
Psoriasis 1.95 1.10–3.46 0.022
Age
435 Years 0.83 0.46–1.52 0.553
Race




Abbreviations: CI, confidence interval; LBW, low birth weight; OR, odds
ratio; PTB, preterm birth.








Preterm birth 1.67 0.82–3.39 0.160
Low birth weight 2.08 0.94–4.57 0.069
Cesarean delivery1 0.79 0.47–1.33 0.367
Spontaneous abortion1 1.10 0.75–1.60 0.640
Abbreviations: CI, confidence interval; LBW, low birth weight; OR, odds
ratio; PTB, preterm birth.
1In these models, propensity scores were calculated on a different set of
covariates (see text).
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psoriasis was not found to be associated with spontaneous
abortion after adjusting for age, race, and assisted reproduc-
tive methods (OR of 1.47, 0.69–3.11).
DISCUSSION
In this retrospective cohort study, psoriasis was associated
with a POC composed of PTB and LBW. Patients with
psoriasis had higher proportion of each the two outcomes
separately, but this was not statistically significant unless they
were combined, as was our a priori specified analysis.
Psoriasis was not found to be associated with cesarean
delivery and spontaneous abortion, but the number of
women with these outcomes was small. Small numbers
precluded the analysis of preeclampsia/eclampsia. The
proportion of POC was similar in patients with mild and
moderate-to-severe disease.
Despite the importance of this subject, very few studies
evaluating the relationship between psoriasis and pregnancy
outcomes have been published. A study performed in the
United States, using health insurance claims data, evaluated
incidence of pregnancy and spontaneous abortion in women
with cutaneous inflammatory diseases, including psoriasis.
There were 197 and 1,699 women in the psoriasis and
comparison groups, respectively. The risk of spontaneous
abortion in the psoriasis group was similar to the risk in the
comparison group (relative risk of 1.1, 95% confidence
interval 1.0–1.2). Although the use of claims data allows
analysis of large number of patients and outcomes, it leads to
potential information bias, with inaccurate diagnoses, thera-
pies, and timing of events. Given that psoriasis is commonly
misclassified as other skin conditions and vice versa, and that
this study included some women with diagnostic codes for
more than one skin condition in the psoriasis group,
misclassification was even more likely (Seeger et al., 2007).
Ben-David et al. (2008) evaluated several outcomes in a
case–control study in Israel, using an obstetrics database. The
study included 145 pregnancies, for which the final outcomes
were known, in 84 women with psoriasis and 860
pregnancies in the control group. Women with psoriasis
had higher odds of recurrent abortion, hypertension, and
cesarean delivery. Given the nature of the database, detailed
information was gathered on the outcomes; however, it is
unclear how accurate the definition of exposure was. This
study also had a small number of outcomes and did not take
into account correlation between multiple pregnancies in the
same woman (Ben-David et al., 2008).
Our study also had limitations intrinsic to a retrospective
study, including the potential for misclassification. This
problem was minimized by confirming exposure status and
outcomes from manual electronic medical records review. A
large number of patients identified in the Research Patient
Data Registry (RPDR) search did not meet the eligibility
criteria in the electronic medical records review, reflecting
that the use of data repository by itself would not be
completely accurate. The definition of the outcomes was
clear and they could be accurately measured. We also
obtained detailed information on several important covari-
ates. There were, however, differences in covariate rates and
associations than those that have been seen in previous
studies. These could reflect issues with data on these
covariates, as the study involved retrospective information
collected from medical records. Some of the covariates,
including obesity, diabetes, and the use of sedative medica-
tions, had an increased odds of the composite outcome;
however, these associations were not statistically significant.
The relatively small sample size was a limitation, given the
rarity of the outcomes. However, the study had enough
power to detect a clinically meaningful and statistically
significant association between psoriasis and the POC. The
limited number of events and pregnancies may have affected
secondary outcomes. Although the requirement of evidence
of outpatient encounter before pregnancy and prenatal care
and labor at any of the PHS institutions attempted to improve
the internal validity of this study, it may have affected the
generalizability of the results to different populations with
access to different levels of care. The prevalence of the POC
in the non-psoriasis group was about 8% and, in 2008,
Massachusetts’ rates of PTB and LBW were 10.8 and 7.8%,
respectively. (CDC, 2008) Knowing that there is evident
overlap between these outcomes, and that, in our study, we
only evaluated singleton pregnancies, which should reduce
the incidence of both these outcomes, the sample evaluated
in this study seems to be comparable to its source population
in terms of the frequency of the main outcomes.
Despite these limitations, the results for the analysis of the
main outcome of interest were robust in our data set: the
effect of psoriasis on the POC remained significant in the
univariable and multivariable analysis, after adjusting for the
clinically important variables, as well as a propensity score
including several important covariates. This finding was also
corroborated in a sensitivity analysis using women’s first valid
pregnancies only, which showed similar effect estimates but
were not statistically significant. In the evaluation of PTB and
LBW separately, preeclampsia/eclampsia, cesarean delivery,
and spontaneous abortion, the small number of these events
could have been responsible for the nonsignificant findings.
We believe that this issue should be assessed further, given
the biological plausibility of the association between
systemic inflammation and both PTB and LBW, in addition
to serious short- and long-term consequences of these
outcomes. Preterm birth is the leading cause of perinatal
morbidity and mortality in developed countries (Slattery and
Morrison, 2002). Both PTB and LBW can also result in
considerable neurodevelopmental and behavioral impair-
ments (Stephens and Vohr, 2009; Stoinska and Gadzinowski,
2011). In view of these potential consequences, it is
important to verify whether pregnancies of women with
psoriasis are at higher risk and determine the effect of disease
activity on the risk. If these risks are verified, it is possible that
some patients with psoriasis should be customarily referred to
high-risk/maternal–fetal medicine services.
The use of a hospital-based design may have introduced
bias that could affect the findings of the study. Larger,
population-based, prospective cohorts are needed to confirm
that an association between psoriasis and adverse outcomes
of pregnancies exists. Ideally, these studies would also
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evaluate whether adequate control of psoriasis could prevent
poor outcomes. Prior studies have shown that therapy
decreases levels of inflammatory cytokines (Strober et al.,
2008; Kagami et al., 2010). Therefore, good control of
disease before conception and during pregnancy may be an
important goal, one that has become both more realistic and
important with the advent of new treatment options and the
ongoing collection of more data about their safety during
pregnancy.
MATERIALS AND METHODS
Study design and population
This is a retrospective cohort study using clinical data from the PHS
in Massachusetts, United States. Institutional Review Board approval
from the Partners Human Research Committee was obtained and
patient consent was not required. The study was conducted in
compliance with the Declaration of Helsinki Principles.
The search flowchart is shown in Figure 1. To identify our cohort
of patients, we searched the RPDR—a large clinical database within
PHS, which includes data from inpatient and outpatient visits. In this
study, patients had been followed up at two large tertiary care
centers: Massachusetts General Hospital and Brigham and Women’s
Hospital. The query tools in RPDR allowed the identification of
selected groups of patients by International Classification of Diseases
ninth revision (ICD-9) codes. The searches for the two exposure
groups, women with psoriasis and women without psoriasis, were
performed separately. For both, the same eligibility criteria were
used, with the exception of psoriasis diagnosis. We queried to
identify women, 18 to 45 years of age, who had at least one code
related to pregnancy between January 1999 and December 2009,
including codes for pregnancy examination or test (ICD-9 V72.4),
normal pregnancy (ICD-9 V22), or any adverse pregnancy outcome.
All women were required to have at least one outpatient encounter
within a year before conception and at least one prenatal visit and
birth at a PHS hospital. These criteria were used to circumvent the
inclusion of women referred to one of the PHS hospitals because of
pregnancy complications or high-risk pregnancies, minimizing
substantial differences between psoriasis and non-psoriasis popula-
tions, and to have more detailed and accurate information on
pregnancy outcomes. We queried to exclude patients in both groups
with diseases that could be related to psoriasis or psoriasis therapy
and also have potential effect on outcomes of pregnancy, such as
inflammatory bowel disease, rheumatoid arthritis, systemic lupus,
and human immunodeficiency virus infection. For the non-psoriasis
group, the search yielded over 130,000 patients. We then randomly
selected 1,104 patients in order to find approximately two eligible
women in the non-psoriasis group for each eligible woman in the
psoriasis group.
Following this, medical records for eligible patients were
reviewed. During the selection process, extraction of information
on exposure and covariates of interest and determination of severity
of disease, the author performing electronic medical records review
(XTL) was blinded to pregnancy outcomes. The majority of patients
excluded in the psoriasis group could not have diagnosis confirmed
by chart review, did not have any pregnancy at PHS after the
diagnosis of psoriasis, or did not have any prenatal visit and/or labor
at PHS. For the non-psoriasis group, the most important reasons for
exclusion were no outpatient encounter during the year before
conception and no prenatal visit and/or birth at PHS.
Data collection
ICD-9 code 696.1 was used to identify patients with diagnosis of
psoriasis. In RPDR, we searched for women who had one diagnostic
code by a dermatologist or at least three encounters coded as 696.1
by a non-dermatologist provider, in order to reduce misclassification
(Icen et al., 2008). A woman would only be included if the diagnosis
of psoriasis could be confirmed by medical record review and was
noted before any of her pregnancies. For women diagnosed with
Data repository search
Psoriasis group (n =444)
Detailed information (n =145)
162 Pregnancies
Detailed information (n =302)
290 Patients included
Excluded from analysis (n =12)
501 Pregnancies
Only SAB, twins or ectopic pregnancies,
congenital abnormalities
122 Patients included
Excluded from analysis (n =23)
Only SAB, twins or ectopic pregnancies,
congenital abnormalities
Patients excluded (n =300):
Diagnosis not confirmed – 104
Diagnosis after pregnancy – 80
No PHS visit within year prior to conception – 16
No pregnancy – 16
Male – 13
Legally induced abortion only – 10
Inactive psoriasis before conception – 9
Lupus, RA, IBD – 5
Out of age range – 1
No EMR notes – 1
One non-dermatologist diagnostic code only – 14
No prenatal visit/labor at PHS – 31
Non-psoriasis group (n =1,104)
Patients excluded (n =802):
No prenatal visit/labor at PHS – 147
No pregnancy – 73
No EMR notes – 51
Legally induced abortion only – 16
Male – 2
Lupus, RA – 2
History of-questionable psoriasis – 2
Out of age range – 1
No PHS visit within year prior to conception – 508
Figure 1. Search flowchart. EMR, electronic medical records; IBD, inflammatory bowel disease; PHS, Partners Healthcare System; RA, rheumatoid arthritis;
SAB, spontaneous abortion.
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psoriasis between pregnancies, only pregnancies that happened after
this diagnosis were included in the analysis.
All outcomes were extracted by medical record review. In the
main analysis, only viable, non-anomalous singleton pregnancies
that happened after 1999 or after the diagnosis of psoriasis, in the
psoriasis group, were included. The primary outcome (POC)
includes PTB, defined as less than 37 gestational weeks, and LBW
(o2,500 g). These outcomes could coexist or occur separately. It
was considered present if one or both components were identified.
In an exploratory manner, we also evaluated the association of
psoriasis with each component of the POC separately, in addition to
preeclampsia/ eclampsia and cesarean delivery. Spontaneous abor-
tion as a first pregnancy at PHS was also assessed.
We collected information on demographics (age, race, marital
status, educational level, hospital, and date of delivery), and
comorbidities known to be associated with psoriasis and that could
also affect pregnancy outcomes, such as depression, hypertension,
diabetes, and obesity.
Obesity was measured using body mass index, collected from the
follow-up visit during the year before conception or until 8 weeks of
pregnancy. Prior diagnosis of diabetes and gestational diabetes
requiring insulin were combined in one category versus no diabetes.
We extracted data on other potential confounders: pregnancy
number; substance (tobacco, alcohol, and illicit drug) abuse, in
addition to use of narcotic or psychotropic medications during
pregnancy; anemia (hematocrito36%) diagnosed in the year before
conception or during first 12 gestational weeks; use of assisted
reproductive technologies (intrauterine insemination or in vitro
fertilization); and infections (chorioamnionitis and symptomatic
urinary tract infections) occurring during pregnancy.
Statistical analysis
Odds ratio between psoriasis and non-psoriasis patients was used as
a measure of association along with 95% confidence interval. All
variables, including the ones previously collected as continuous,
such as age and body mass index, were presented as categorical to
facilitate interpretability. We also performed the multivariable
analysis with them as continuous variables and the results were
similar. Given the small number of patients in some categories, we
decided to collapse them when clinically meaningful. Patients were
classified as younger or older than 35 years of age and body mass
index was analyzed using the following categories: normal weight
(18.5–24.9 kgm2), overweight (25–29.9 kgm2), and obese
(X30 kgm2).
Based on previous studies of inflammatory bowel disease and
pregnancy outcomes, we expected to find an OR of approximately
1.8 and 11% incidence of the POC in the non-exposed group.
(Cornish et al., 2007; CDC, 2008) To obtain an a-value of 0.05 and
power of 85%, a total number of 300 patients per group would be
necessary. However, using the RPDR, there were 145 eligible
women in the psoriasis group. Two new power calculations were
then performed: taking into account the final number of women and
the total number of pregnancies. The power varied from 65% to
80%, respectively.
Univariable and multivariable analyses were performed to
identify the relationship between psoriasis and other variables with
the POC. Given that women could have more than one pregnancy,
we used repeated measures analysis to account for the multiple
pregnancies in the same woman. The method of generalized
estimating equations was used to model the association of odds of
POC with psoriasis while adjusting for potentially confounding
variables. As a sensitivity analysis, we evaluated whether the
association of psoriasis with POC was similar when only the first
pregnancy at PHS for each woman was included in the analysis.
Age, body mass index, hypertension, diabetes, substance
abuse, anemia, use of assisted reproductive technology methods,
number of pregnancy, year of delivery, and infections were
measured as time-varying variables. The remaining variables,
including psoriasis, were considered to be time-stationary. Depres-
sion and hypertension were considered to be constant over time,
because they either persisted or patients were on treatment for them
in subsequent pregnancies.
The multivariable modeling strategy was performed in two ways.
First, the multivariable model contained psoriasis and some of the
most important clinical covariates, including age, race, and assisted
reproductive technologies. We evaluated the remaining covariates
for confounding (more than 10% change in the effect estimate for
psoriasis), which would be included in the multivariable model. In
the second strategy, because of the small number of outcomes, we
used propensity score analysis. By using logistic regression, the
propensity score was calculated with psoriasis as the dependent
variable and all other covariates in the first pregnancy as
independent variables. The distribution of propensity scores, OR,
and 95% confidence interval for the covariates of the propensity
score regression model are provided in Supplementary Tables S1 and
S2 online.
In the analysis of spontaneous abortions, given the small number
of events, we were not able to analyze the effect of psoriasis on
spontaneous abortion in multiple pregnancies per woman. We
decided to model this association using the first pregnancy at PHS
only. The analysis was performed using SAS 9.2 (SAS Institute,
Cary, NC).
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